Jim Cramer on Pfizer: “The Drug Stocks Are Just in a World of Hurt, and This One Continues to Be There”

Group 1 - Pfizer Inc. has a current yield of 7% and recently acquired Seagen, but the drug stocks, including Pfizer, are facing significant challenges [1][2] - The market perception of Pfizer is that it lacks compelling offerings, with the Seagen acquisition not meeting expectations [2] - Despite the challenges, there is a belief that Pfizer could still find a way to improve its situation, similar to how various players in the cholesterol market have succeeded [2]